We found that tumor cells and patient-derived xenografts (PDXs) respond more strongly to a CDK inhibitor when they express high levels of CDK4 but exhibit resistance to the CDK inhibitor when they express high levels of p16ink4a. This evidence concerns the gene CDK4 and neoplasm.